Key result
Irbesartan reduced blood pressure (P=0.02 for systolic) and slightly reduced the isoproterenol-induced glycerol response in adipose tissue (P<0.05) without affecting skeletal muscle metabolism.
Why the study?
Does irbesartan alter tissue metabolism in obese men?
RCT (n=14)
Double-blind
Does irbesartan alter tissue metabolism in obese men?
p-value: p=<0.05
AT1 receptor blockade with irbesartan in obese men does not reveal a major tonic ANG II effect on skeletal muscle metabolism but may slightly increase adipose tissue lipolysis.
Irbesartan shows limited metabolic effects beyond BP reduction in obese men; challenges major tonic ANG II influence on skeletal muscle metabolism.
ANG II applied to the interstitial space influences carbohydrate and lipid metabolism in a tissue-specific fashion. Thus endogenous ANG II may have a tonic effect on tissue metabolism that could be reversed with ANG II type 1 (AT1) receptor blockade, particularly during adrenergic stimulation. We studied 14 obese men. They were treated for 10 days with the AT1 receptor blocker irbesartan or with placebo in a double-blind and crossover fashion. At the end of each treatment period, we assessed skeletal muscle and adipose tissue metabolism using the microdialysis technique. The ethanol dilution technique was applied to follow changes in tissue blood flow. Measurements were obtained at baseline and during application of incremental isoproterenol concentrations through the microdialysis catheter. Blood pressure decreased from 133 +/- 3/84 +/- 3 to 128 +/- 3/79 +/- 2 mmHg for systolic and diastolic blood, respectively (P = 0.02 and 0.006, respectively) with AT1 receptor blockade. Isoproterenol perfusion caused a dose-dependent increase in dialysate glycerol in adipose tissue and in skeletal muscle. Irbesartan slightly reduced the isoproterenol-induced glycerol response in adipose tissue (P < 0.05 by ANOVA). Ethanol ratio, interstitial glucose supply, and lactate production in adipose tissue and skeletal muscle were similar with placebo and irbesartan. We conclude that AT1 receptor blockade in obese men does not reveal a major tonic ANG II effect on interstitial glucose supply, lipolysis, or glycolysis in skeletal muscle, either at rest or during beta-adrenergic stimulation. Endogeneous ANG II may slightly increase adipose tissue lipolysis. The mechanism may promote the redistribution of triglycerides from adipose tissue toward other organs.
No takes yet. Share an insight, caveat, or question.
Boschmann et al. (2005) conducted an RCT in Obesity (n=14). Irbesartan vs. Placebo was evaluated on Isoproterenol-induced glycerol response in adipose tissue (p=<0.05). Irbesartan reduced blood pressure (P=0.02 for systolic) and slightly reduced the isoproterenol-induced glycerol response in adipose tissue (P<0.05) without affecting skeletal muscle metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: